New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 120ug; ribavirin 200mg;   - combination - 200mg/120mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 120ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 150ug; ribavirin 200mg;   - combination - 200mg/150mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 150ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 50ug; ribavirin 200mg;   - combination - 200mg/50mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 50ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - boceprevir 200 mg - capsules - boceprevir - victrelis (boceprevir) is indicated for the treatment of chronic hepatitis c genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - boceprevir 200 mg - capsules - boceprevir - victrelis (boceprevir) is indicated for the treatment of chronic hepatitis c genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - boceprevir - capsule - 200mg

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - peginterferon alfa-2b - hepatitis c, chronic - immunostimulants, - adults (tritherapy)pegintron in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.please refer to the ribavirin and boceprevir summaries of product characteristics (smpcs) when pegintron is to be used in combination with these medicines.adults (bitherapy and monotherapy)pegintron is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv.pegintron in combination with ribavirin (bitherapy) is indicated for the treatment of chc infection in adult patients who are previously untreated including patients with clinically stable hiv co-infection and in adult patients who have failed previous treatment with interferon-alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon-alpha monotherapy.interferon monotherapy, including pegintron, is indicated mainly in case of intolerance or contraindication to ribavirin.please refer to the ribavirin smpc when pegintron is to be used in combination with ribavirin.paediatric population (bitherapy)pegintron is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents who have chc, previously untreated, without liver decompensation, and who are positive for hcv-rna.when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. the decision to treat should be made on a case-by-case basis.please refer to the ribavirin smpc for capsules or oral solution when pegintron is to be used in combination with ribavirin.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd  - peginterferon alfa-2b - hepatitis c, chronic - immunostimulants, - adults (tritherapy)viraferonpeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.please refer to the ribavirin and boceprevir summaries of product characteristics (smpcs) when viraferonpeg is to be used in combination with these medicines.adults (bitherapy and monotherapy)viraferonpeg is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv.viraferonpeg in combination with ribavirin (bitherapy) is indicated for the treatment of chc infection in adult patients who are previously untreated including patients with clinically stable hiv co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon alpha monotherapy.interferon monotherapy, including viraferonpeg, is indicated mainly in case of intolerance or contraindication to ribavirin.please refer to the ribavirin smpc when viraferonpeg is to be used in combination with ribavirin.paediatric population (bitherapy)viraferonpeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, previously untreated, without liver decompensation, and who are positive for hcv-rna.when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. the decision to treat should be made on a case-by-case basis.please refer to the ribavirin smpc for capsules or oral solution when viraferonpeg is to be used in combination with ribavirin.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - nevirapine - tablets - nevirapine 200 mg - nevirapine - nevirapine - for use in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Israel - English - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.